Mild illness at or after measles vaccination does not reduce seroresponse in young children.

We analyzed data from a randomized trial of AIK-C, high-titre (EZ-H) or medium-titre EZ (EZ-M) vaccines in 3.5 and 6 month old infants in Kinshasa, Zaire, in which the occurrence of rhinorrhoea, cough, diarrhoea, fever, conjunctivitis or rash was monitored for 15 days post-vaccination (including the day of vaccination, day 0). We compared sero-response at 6 weeks and 6 months post-vaccination among children with and without mild illness at or after vaccination. Seroresponse tended to be higher in children with mild illness after vaccination than those without, whether days 0-7 or 8-15 were examined. For most symptoms, these differences did not reach statistical significance after adjusting for prevaccination maternal antibody level. However, in the EZ-M group, the proportion of children attaining at least the median post-vaccination antibody level was significantly higher in children with rhinorrhoea in days 0-7 post-vaccination than those without (adjusted odds ratio 2.6, 95% CI 1.08-6.27), as was that among children with at least one symptom in days 0-7 compared with children with no symptoms (adjusted OR 4.55, 95% CI 1.18-17.57). There were no significant differences in post-vaccination antibody levels among children with symptoms compared either to those without the specific symptom or those with no symptoms. Fever on the day of vaccination or at home visits on 7, 10 or 14 days post-vaccination, did not affect seroconversion or GMTs. Regression models showed no relation between the cumulative number of days with symptoms and antibody increase after vaccination. Analysis of antibody levels at 6 months post-vaccination showed no consistent differences according to presence or absence of symptoms. These findings provide further strong support to recommendations that mild illness is not a reason to delay measles vaccination.